<DOC>
	<DOCNO>NCT00116805</DOCNO>
	<brief_summary>The primary objective study compare efficacy , safety , tolerability tenofovir disoproxil fumarate ( TDF ) versus adefovir dipivoxil ( ADV ) treatment HBeAg-positive chronic hepatitis B . Participants receive TDF ADV 48 week ( double-blind ) . After 48 week , eligible participant switch open-label TDF 480 week .</brief_summary>
	<brief_title>A Study Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil Treatment HBeAg-Positive Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<criteria>Key A patient must meet follow inclusion criterion eligible participation study : Chronic hepatitis B virus ( HBV ) infection , define positive serum hepatitis B santigen ( HBsAg ) 6 month 18 69 year age , inclusive Active hepatitis B eantigen ( HBeAg ) positive chronic HBV infection , follow : HBeAg positive screening Alanine aminotransferase ( ALT ) level &gt; 2 × ULN ≤ 10 × upper limit normal range ( ULN ) Serum HBV DNA &gt; 1 million copies/mL screen creatinine clearance ≥ 70 mL/min hemoglobin ≥ 8 g/dL neutrophil ≥ 1,000 /mL Knodell necroinflammatory score ≥ 3 Knodell fibrosis score &lt; 4 ; however , 96 patient cirrhosis , ie , Knodell fibrosis score equal 4 , eligible enrollment Negative serum βhuman chorionic gonadotropin ( hCG ) Nucleotide naïve , ie , prior nucleotide ( TDF ADV ) therapy &gt; 12 week Nucleoside naïve , ie , prior nucleoside ( nucleoside ) therapy &gt; 12 week Willing able provide write informed consent Liver biopsy perform within 6 month baseline readable biopsy slide agree biopsy perform prior baseline Key A patient meet follow exclusion criterion enrol study : Pregnant woman , woman breast feed believe may wish become pregnant course study Males females reproductive potential unwilling use effective method contraception study ; male , condom use female , barrier contraception method use Decompensated liver disease define conjugated bilirubin &gt; 1.5 x ULN , prothrombin time ( PT ) &gt; 1.5 x ULN , platelets &lt; 75,000/mL , serum albumin &lt; 3.0 g/dL , prior history clinical hepatic decompensation ( eg , ascites , jaundice , encephalopathy , variceal hemorrhage ) Received nucleoside , nucleotide ( TDF ADV ) interferon ( pegylated ) therapy within 6 month prior pretreatment biopsy Evidence hepatocellular carcinoma ( HCC ) , ie , αfetoprotein &gt; 50 ng/mL Coinfection hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , hepatitis delta virus ( HDV ) Significant renal , cardiovascular , pulmonary , neurological disease Received solid organ bone marrow transplantation Is currently receive therapy immunomodulators ( eg , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion Has proximal tubulopathy Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>tenofovir</keyword>
	<keyword>adefovir</keyword>
	<keyword>hepatitis B</keyword>
	<keyword>HBeAg Positive</keyword>
</DOC>